DaVita
DaVita Inc. (NYSE: DVA) provides kidney care, primarily through dialysis services for patients with chronic kidney failure and end-stage kidney disease in the United States and internationally. Its U.S. dialysis business includes outpatient and hospital-based hemodialysis, home hemodialysis and peritoneal dialysis,… From the company’s description.
In fiscal 2025, DaVita reported revenue of $13.64B, up 6.5% from fiscal 2024, and net income of $1.08B. Its operating margin was 15.0%, and operations generated $1.89B in cash. Over the twelve months to Jun 30, 2026, revenue was $14.01B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What DaVita does
In the company’s own words
DaVita Inc. (NYSE: DVA) provides kidney care, primarily through dialysis services for patients with chronic kidney failure and end-stage kidney disease in the United States and internationally. Its U.S. dialysis business includes outpatient and hospital-based hemodialysis, home hemodialysis and peritoneal dialysis, related laboratory testing, and center management services. The company also provides integrated kidney care and disease management to patients with chronic and end-stage kidney disease through arrangements with health plans and government programs, alongside clinical research, transplant software and kidney-care-focused investments. DaVita reports U.S. dialysis as its largest business, accounting for approximately 86% of consolidated revenue in 2025; its other operations include U.S. integrated kidney care, other ancillary services and international dialysis. At December 31, 2025, DaVita served approximately 200,500 U.S. dialysis patients through 2,657 outpatient centers and operated or provided services to 585 international centers in 14 countries, serving about 94,500 patients. Its website is http://www.davita.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- DENVER, CO
- Fiscal year end
- December
- CIK
- 927066
- SIC
- 8090
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns DaVita — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in DaVita · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · DaVita’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
DaVita’s bonds, as funds hold them
Funds report holding 4 issues of DaVita’s debt, $2.29B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 5.15%, maturing 2030 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do DaVita and its peers compare on margins and cash generation over ten years?”
- “Where did five years of DaVita's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in DaVita's last four quarterly filings that the numbers alone won't show?”